Turning a corner: Private market posts best month in yearsCore private market metrics suggest positive momentum is brewing and investor sentiment is improving
Turning a corner: Private market posts best month in years
Trading
Data
Solutions
Insights
About
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 11/29/2017 | Series C | $76.37MM raised | $XXX.XX | $XXX.XX |
| 1/26/2016 | Series B | $61MM raised | $XXX.XX | $XXX.XX |
| 11/25/2015 | Series A | $31MM raised | $XXX.XX | $XXX.XX |
